Self-Injection of Insulin Using Appropriate Supportive Devices in Handicapped Subjects with Diabetes

Masuda, Kiyomi; Aoki, Kazutaka; Kikuchi, Kaori; Nezu, Uru; Muraoka, Tomonori; Shinoda, Kazuaki; Nakamura, Akinobu; Shibuya, Makoto; Takáhashi, Mayumí; Kimura, Mari; Terauchi, Yasuo

doi:10.1089/dia.2009.0193

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 reported that initial treatment using insulin or an α‐glucosidase inhibitor (αGI) was a risk factor for early non‐persistence and the discontinuation of treatment 3 . Recently, we reported that existing or newly manufactured supportive devices can enable handicapped patients to self‐inject insulin, and this delivery route might improve adherence to insulin treatment 4 . At least three reasons exist for the poor adherence to αGI treatment: (i) the need to take the medicine just before meals; (ii) adverse gastrointestinal effects; and (iii) the need to take the medicine three times a day.…”

Section: Introductionmentioning

confidence: 99%

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance

Masuda

Aoki

Terauchi

2011

Journal of Diabetes Investigation

Self Cite

View full text Add to dashboard Cite

Aims/Introduction: One of the reasons for the poor adherence to α‐glucosidase inhibitor (αGI) treatment is the need to take medication three times a day. We hypothesized that the administration of miglitol might be effective for the next meal if the miglitol‐induced inhibition of α‐glucosidase activity persists until the next meal. In the present study, we evaluated whether the administration of miglitol just before or after breakfast was effective for postprandial glucose excursion after lunch without taking miglitol at lunch.Materials and Methods: We measured the plasma glucose, serum insulin and glucagon, plasma active glucagon‐like peptide‐1 (GLP‐1), and total glucose‐dependent insulinotropic polypeptide levels in non‐diabetic men. Miglitol was given to each patient according to four different intake schedules (control: no drug; intake 1: drug given just before breakfast [50 mg]; intake 2: drug given 30 min after the start of breakfast [50 mg]; intake 3: drug given at the same time as intake 2, but without eating breakfast [50 mg]).Results: Both intake 1 and intake 2 had a smaller area under the curve (AUC) for plasma glucose excursion after lunch, compared with the control. Intake 2 had a larger AUC for active GLP‐1 after lunch, compared with intake 1.Conclusions: Intake 1 and intake 2 can improve postprandial hyperglycemia after lunch. The results of the present study raise the possibility that the administration of miglitol twice a day might be effective and might help to improve treatment adherence among diabetic patients. This trial was registered with UMIN Clinical Trial Registry (no. UMIN000002896). (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2011.00129.x, 2011)

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance

Masuda

Aoki

Terauchi

2011

Journal of Diabetes Investigation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Insulin administration is usually performed by various pens [20]. Supportive devices might be helpful for handicapped patients [21].…”

Section: Application Of Insulinmentioning

confidence: 99%

Insulin therapy

Lechleitner

Hoppichler

2011

Wien Med Wochenschr

View full text Add to dashboard Cite

Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus. In type 2 diabetes, insulin is indicated if glycaemic goals are not reached by oral anti diabetics, as well as for metabolic detoriation, co-morbidities, surgery, pregnancy or contradictions against oral anti diabetics. Insulin preparations are characterized by the onset of the insulin action, the peak profile and duration of action. Available are short acting, long-acting and premixed preparations of human insulin, and insulin analogues. The gold standard of insulin therapy in type 1 diabetes is functional insulin therapy with a basal-bolus insulin regimen and control and adaption of the therapy by the patient. Various insulin regimens are available for treating patients with type 2 diabetes, including basal insulin supported oral therapy, supplementary mealtime injection of short acting insulin or insulin analogues, conventional insulin therapy or a basal bolus procedure. The various insulin preparations and regimens make it possible to adapt the therapy according to the patient's individual need.

show abstract

Current literature in diabetes

2010

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 26 sections: 1 Reviews; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Obesity; 7 Prediction and Prevention; 8 Intervention: a) General; b) Care; c) Drug Therapy; d)Economics; e) Gene therapy; f) Nursing; g) Nutrition; h) Surgery; i) Transplantation; 9 Pathology and Complications: a) General; b) Cardiovascular; c) Eye disease; d) Gestational and fetal; e) Neurological; f) Podiatrical; g) Renal; 10 Endocrinology & Metabolism; 11 Experimental Studies; 12 Diagnosis and Techniques. Within each section, articles are listed in alphabetical order with respect to author

show abstract

Self-Injection of Insulin Using Appropriate Supportive Devices in Handicapped Subjects with Diabetes

Abstract: Existing or newly manufactured supportive devices can enable handicapped subjects to self-inject insulin.

Cited by 5 publications

References 15 publications

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance

Insulin therapy

Current literature in diabetes

Contact Info

Product

Resources

About